U.S. markets closed

Vaxart, Inc. (VXRT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.74+1.57 (+21.90%)
At close: 4:00PM EDT
Sign in to post a message.
  • P
    I'm thinking of adding more tomorrow. I consider anything under $10 is a gift for such a potential game changer. Think of this: COVID-19 vaccine in the mail containing tablets! No need to stay up at midnight trying to get an appointment for vaccination.
  • B
    If you look at the VXRT results to date and consider the performance of other vaccine firms in this market,
    i really believe this has a chance to hit $50, $100 or higher longer term, just IMO.
  • J
    That's a pretty big bull pennant on Friday. Second half of the flagpole should land somewhere between 11 and 12, should it play out. Spare me all the bearish commentary I already know what this stock is, it's a speculative biotech company which is more than enough to drive interest because essentially they have a potentially groundbreaking product.
  • J
    just like Arby's has the meat Vaxart illicits the T Fighter and Helper Cells with the memory that lasts a lifetime not just months. stay long vxrt and forget about it till the world gets the flick. then it will see over 100 a share.
  • A
    The short volume ratio shot up to 37% today at a borrow fee rate of 5.7%.
    We need one more good news next week to squeeze them out.
    Shorts are still dreaming... lol
  • W
    Lets have another awesome week. Friday's spike was just the beginning, we have so much more to climb. 52 week high maybe soon! I love this stock.
  • J
    (Updated - June 11, 2021 10:12 AM EDT)

    Piper Sandler analyst Yasmeen Rahimi initiates coverage on Vaxart Inc. (NASDAQ: VXRT) with a Overweight rating and a price target of $18.00.

    The analyst commented, "We are initiating coverage on Vaxart, Inc (VXRT) with an Overweight rating and $18 price target. VXRT is a clinical-stage biotech developing seven oral vaccines: five in the clinic for COVID-19, norovirus, and influenza; and two in preclinical stages for RSV and HPV.At the core is VAAST, a thoughtfully designed, novel adenoviral type5 + TLR3-adjuvant platform, providing six key advantages (pgs 9-11). Notably, Ad5 is validated in 200 clinical studies, de-risking the vector for approval due to regulator familiarity. Additionally, VAASThas been significantly de-risked through five clinical datasets showing safety and efficacy in 580 healthy patients, increasing our conviction in an insulated pipeline with potent and safe drug candidates, which gives a high success rate to seven catalysts through 2022."

    For an analyst ratings summary and ratings history on Vaxart Inc. click here. For more ratings news on Vaxart Inc. click here.

    Shares of Vaxart Inc. closed at $7.17 yesterday.
  • A
    A Magnum
    This post is for those posters that asked why day/swing-trade for a few cents?
    As posted 6/8/21 “VXRT popped out of the Bollinger Ban. IMHO technically has a very good chance moving into the $8.00 to $11.00 range”. As a swing trader the $8.00 GTC sell day orders were filled yesterday at $8.00 while $9.00, $10.00 and $11.00 still remained open. Closed that day.
    1) The $8.00 sell orders filled from $7.13 buys the morning of 6/8/21 netted 12.2%.
    2) Using those proceeds, added/bought 12% more share market-at-close … $7.17.
    Not sure what tomorrow will bring, but I have a plan.

    Day/swing-trade, that actually make money utilize the basic 3 Rules of Investing:
    1) Know WHY you’re Buying or Investing.
    2) Know WHAT you are buying; Balance Sheets and Income Statements is a MUST read.
    3) Know and set GOALS with a “Short-term” time goals. My goal is to “double my money” within a reasonable time frame.

    So today’s buy transaction and yesterday's sell, met my goals; every 8th trade of 12% or more will than double my money, BUT not all trades work out as expected; that’s why there are stop loss orders (per preplanned goals “such as I will not lose more that 12%” you’ll need about 14% to get back to even, the your back to “I should a”. That's why all the bashers.

    I’m Bullish VXRT and see further upside, expect to make 8 to 10 more full-boat (Buy and sell) trades here before the end of the month. Long, strong and Happy Investing!
  • M
    Short quote and shares outstanding is compareable to 3d systems...3d went from 10 to 56 within a month ...i expect similiar price action here...very soon...
  • R
    Imagine waking upto $50 tomorrow 😂
  • M
    Insiders know something, the third pump had the largest amount of volume inflow and it looked to be done more by institutions than retail traders. Another indicator is the way we held flat right after the pump, then slowly rising until we got the Piper Sandler’s coverage which I think is a divert tactic so whales can come in and add a bunch of shares without causing a big scene. Im expecting a big PR soon 🚀🚀
  • G
    Shares of Vaxart (NASDAQ:VXRT) are up more than 16% to $8.37 in afternoon trading after Piper Sandler initiated coverage with an overweight rating and a $18 price target.
    Analyst Yasmeen Rahimi notes that the company has five oral vaccines in the clinic: for COVID-19, norovirus, and influenza.
  • L
    Lucky G
    I own vxrt for innovative vaccine delivery srne for testing and curing if one didn't get vaccine. Covers all the bases and liking what I'm reading and seeing. Thanks to all posters of good dd. Long and very pleased.
  • W
    If we dip at all tomorrow I'll be doubling my position. It's going to be a great week. Go Vxrt.
  • M
    That cup and handle on the 3 month chart is looking very Bullish. When that handle gets pulled back there's going to be some spring in it to send us straight to 20
  • G
    Vaxart rating positive causing premarket rise in price.

    I am bullish on Vaxart.

    Piper Sandler analyst Yasmeen Rahimi initiates coverage on Vaxart (NASDAQ:VXRT) with a Overweight rating and announces Price Target of $18.

    Rank : positive
  • A
    <Financial Analysts Coverages >
    Jun 2021 Piper Sandler Initiates Coverage On Overweight (Price Target of $18)
    Aug 2020 HC Wainwright & Co. Maintains Buy
    Jul 2020 B. Riley Securities Initiates Coverage On Buy

    An overweight rating on a stock usually means that it deserves a higher weighting than the benchmark's current weighting for that stock. An overweight rating on a stock means that an equity analyst believes the company's stock price should perform better in the future.
  • A
    +20% on more analysts coverage,
    +30% on P2 announcement,
    +15% on Lawsuit dismiss, and
    +20% on P1/2 of other variants.
    I'm not even including funding, JNJ deal and buyout.
    This summer is going to be fun!
  • T
    VXRT will easily surpass its $18 Price Target Estimate that analysts are projecting so simply ignore ALL short bashers who definitely are NOT analysts. No reason to bash them back because no real investor should ever care about what they say
  • A
    <Key Market Event to Watch Next Week >
    The Fed's monetary policy decision and press conference from Fed Chair Jerome Powell will take place Wednesday afternoon. The focal points for investors will be around commentary about the strength of the economic recovery, and remarks that might suggest when the central bank will begin tapering its crisis-era asset purchase program.